Published in Gastroenterology on September 18, 2009
Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol (2010) 3.30
Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol (2014) 2.85
Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology (2013) 2.03
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology (2012) 1.12
Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology (2011) 1.07
Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Aliment Pharmacol Ther (2010) 1.04
A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol (2011) 0.96
Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology (2011) 0.95
Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) (2011) 0.95
Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2011) 0.90
Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. AJR Am J Roentgenol (2012) 0.89
Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy. N Am J Med Sci (Boston) (2014) 0.88
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology (2011) 0.85
Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progression. Aliment Pharmacol Ther (2014) 0.84
Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One (2014) 0.83
Host genetics predict clinical deterioration in HCV-related cirrhosis. PLoS One (2014) 0.81
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int (2016) 0.79
Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study. Dig Dis Sci (2011) 0.79
Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract (2013) 0.77
Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis. PLoS One (2014) 0.75
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75
Development of Serum DHCR24 Antibody as a Marker for Hepatocellular Carcinoma: The End of the Beginning. EBioMedicine (2015) 0.75
Liver failure after hepatocellular carcinoma surgery. Langenbecks Arch Surg (2014) 0.75
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology (2000) 9.74
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Natural history of chronic hepatitis C. Hepatology (2002) 7.70
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology (1997) 5.53
Global challenges in liver disease. Hepatology (2006) 4.55
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology (2007) 3.61
The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology (2000) 3.53
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology (2008) 2.66
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut (2005) 2.39
The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology (2006) 2.35
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut (2004) 2.22
Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (1998) 2.06
AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol (1998) 1.97
Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut (2004) 1.93
Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology (2005) 1.85
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Which patients with hepatitis C develop liver complications? Hepatology (2000) 1.73
Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut (1999) 1.49
Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol (2002) 1.44
Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology (2007) 1.40
The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology (1999) 1.39
Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol (1997) 1.39
Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol (2004) 1.23
Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol (2004) 1.20
Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites. Am J Gastroenterol (2003) 1.14
Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology (2008) 1.04
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther (2007) 0.99
The impact of diabetes and obesity on liver histology in patients with hepatitis C. Diabetes Obes Metab (2003) 0.97
Limitation of the model for end-stage liver disease for outcome prediction in patients with cirrhosis-related complications. Clin Transplant (2006) 0.84
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med (2010) 7.95
Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med (2007) 7.90
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA (2006) 7.60
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med (2002) 6.64
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med (2011) 6.31
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology (2004) 5.83
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
AASLD position paper: the management of acute liver failure. Hepatology (2005) 5.09
Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr (2008) 5.01
Alcoholic hepatitis. N Engl J Med (2009) 4.98
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2003) 4.95
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A (2006) 4.84
The prevalence of celiac disease in the United States. Am J Gastroenterol (2012) 4.77
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Daily activity energy expenditure and mortality among older adults. JAMA (2006) 4.36
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology (2003) 4.33
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Prevalence of estimated GFR reporting among US clinical laboratories. Am J Kidney Dis (2008) 3.55
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35